HIV treatment adherence, drug resistance, virologic failure: Evolving concepts

Jean B. Nachega, Johns Hopkins University
Vincent Marconi, Emory University
Gert U. van Zyl, Stellenbosch University
Edward M. Gardner, University of Colorado
Wolfgang Preiser, Stellenbosch University
Steven Y. Hong, Tufts University
Edward J. Mills, University of British Columbia
Robert Gross, University of Pennsylvania

Journal Title: Infectious Disorders - Drug Targets
Volume: Volume 11, Number 2
Publisher: Bentham Science Publishers | 2011-04-25, Pages 167-174
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.2174/187152611795589663
Permanent URL: https://pid.emory.edu/ark:/25593/rrwzt

Final published version: http://dx.doi.org/10.2174/187152611795589663

Accessed June 8, 2018 1:10 AM EDT
HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts

Jean B. Nachega¹,²,*, Vincent C. Marconi⁴, Gert U. van Zyl²,³, Edward M. Gardner⁵, Wolfgang Preiser²,³, Steven Y. Hong⁶, Edward J. Mills⁷, and Robert Gross⁸

¹Departments of International Health and Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
²The Department of Medicine and Centre for Infectious Diseases, Stellenbosch University, Faculty of Health Sciences, Cape Town, South Africa
³Department of Pathology, Division of Medical Virology, Stellenbosch University, Faculty of Health Sciences, Cape Town, South Africa
⁴Emory University School of Medicine, Atlanta, Georgia, USA
⁵Denver Public Health and The University of Colorado, Denver, USA
⁶Tufts University School of Medicine, Boston, USA
⁷British of Columbia-Centre for Excellence on HIV/AIDS, University British of Columbia, Vancouver, Canada
⁸Department of Medicine, Division of Infectious Diseases and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA

Abstract

Poor adherence to combined antiretroviral therapy (cART) has been shown to be a major determinant of virologic failure, emergence of drug resistant virus, disease progression, hospitalizations, mortality, and health care costs. While high adherence levels can be achieved in both resource-rich and resource-limited settings following initiation of cART, long-term adherence remains a challenge regardless of available resources. Barriers to optimal adherence may originate from individual (biological, socio-cultural, behavioral), pharmacological, and societal factors. Although patients and providers should continuously strive for maximum adherence to cART, there is accumulating evidence that each class of antiretroviral therapy has specific adherence-drug resistance relationship characteristics allowing certain regimens more flexibility than others. There is not a universally accepted measure for cART adherence, since each method has distinct advantages and disadvantages including cost, complexity, accuracy, precision, intrusiveness and bias. Development of a real-time cART adherence monitoring tool will enable the development of novel, pre-emptive adherence-improving strategies. The application of these strategies may ultimately prove to be the most cost-effective method to reduce morbidity and mortality for the
individual and decrease the likelihood of HIV transmission and emergence of resistance in the community.

Keywords
HIV; antiretroviral therapy adherence; virologic failure; drug resistance; outcomes

1. INTRODUCTION

Medication adherence typically refers to the extent to which individuals take medications as prescribed. Optimal adherence to combination antiretroviral therapy (cART) can be defined based on the virologic (measured by HIV RNA viral load), immunologic (measured by CD4 T-cell count), and clinical outcomes of patients whose adherence was measured during longitudinal studies. For the currently out-moded unboosted protease inhibitor (PI)-based cART, Paterson et al. described the highest likelihood of treatment success in patients who take ≥95% of the medications prescribed by their physician [1]. In contrast, accumulating data shows that cART based on non-nucleoside reverse transcriptase inhibitors (NNRTIs) or boosted PIs have high rates of suppression at moderate levels of adherence (70-90%) [2-6].

It is now widely appreciated that adherence to antiretroviral therapy is the critical determinant of HIV treatment outcomes. Adherence to cART had been shown to be a major predictor of achieving adequate suppression of HIV replication [1-6], required to minimize the emergence of drug resistance (DR) [7], disease progression [8], and death [9-11]. Recently, there has been increasing discussion regarding the public health implications of antiretroviral therapy utilization and adherence as applied in ‘test and treat’ HIV prevention strategies [12]. Here, we will explore these principles in further detail. In addition, we will review levels of adherence to antiretroviral therapy in different populations, the association between adherence and the development of antiretroviral resistance mutations, the impact of adherence on the cost of medical care, and finally discuss the instruments used to measure adherence and their potential utility to impact HIV treatment outcomes in the future.

2. ADHERENCE AS MAJOR DETERMINANT OF HIV TREATMENT OUTCOMES: CLINICAL AND PUBLIC HEALTH

Some determinants of effective treatment of HIV infection include biology, behavior, and social or structural issues. A conceptual "pathway" model of successful HIV treatment determinants and outcomes illustrates the critical role of medication adherence Fig. (1). Biological determinants of adherence include predisposition to drug adverse effects (e.g., Abacavir hypersensitivity reaction and HLA B*5701) [13]. Behavioral determinants include issues such as maintenance of routines [14-15]. Social issues include stigma in the local community regarding HIV infection [16-17]. Structural issues relate to the health care system which includes the development and availability of potent medications, adoption of guidelines for correct prescribing of these drugs, and regular patient access to health care and medications [18-20]. Optimizing all of these factors will most likely lead to the highest levels of adherence possible.
The pathway to adherence is threatened by the complexity of cART regimens. Fortunately, a South African patient initiating cART today is typically prescribed three individual tablets once a day: Tenofovir (TDF) 300mg + Lamivudine (3TC) 300 mg or Emtricitabine (FTC) 200 mg + Efavirenz (EFV) 600mg [21]. The pill burden can be simplified further by using medications that combine several drugs in a single pill as fixed-dose combinations (FDC). In other settings such as high-income countries, a one pill once a day combination of EFV + FTC + TDF in the same dosage as the individual tablets is commonly used [22].

On a once daily cART regimen, in order to remain >95% adherent to cART, a patient can miss no more than one out of the 30 doses per month. In addition, for maximal efficacy, specific cART doses must be taken at the prescribed time. When patients do not accurately adhere to their regimen schedule and instead take their drugs too late or too early or miss doses completely, blood concentrations can drop below the level necessary to fully suppress HIV, which may lead to the emergence of drug-resistance, disease progression and death, or rise to levels that are hazardous to the patient because of drug toxicity [23-24]. Unfortunately, how precisely the timing needs to be followed before virologic failure is not fully characterized and likely differs by HIV drug/ regimen [25]. A significant body of evidence has demonstrated the relationship between the presence of acquired HIVDR and AIDS/death outcomes [26-35]. In addition, data from CDC’s HIV Outpatient Study showed that patients who had resistance testing survived longer than those who did not. However, it is unlikely that testing per se was life-saving but served as an indicator of better care and better access to newer drugs [36].

Evidence from observational studies among heterosexual populations and men who have sex with men suggests that effective cART in highly adherent patients may greatly reduce sexual transmission of HIV from infected individuals to their sexual partners [37-38]. This concept has been explored in a modeling exercise that simulated the effects of a hypothetical “test-and-treat” strategy in which universal voluntary HIV testing is combined with immediate cART for infected persons regardless of their CD4 T-cell count. Based on these modeling data, and assuming sustained high levels of adherence with broad coverage and uptake, cART could reduce HIV transmission, and hence potentially curb the HIV epidemic by decreasing the incidence of HIV to less than one case per 1,000 people per year by 2016 [39-42]. However, achieving full access to cART and long-term ART adherence support for all at-risk populations may prove to be more difficult than any mathematical model could predict [40-41] and such approaches still raise concerns about individual rights, toxicity, drug resistance, financing. Also, as for all mathematical models, the voluntary “test-and-treat” model is based on a number of assumptions that required to be validated by research. Indeed, feasibility studies are already underway in both developed and developing countries with preliminary results anticipated in the next few years.

The major issue facing the developing world is the scaling up of cART access. This depends on political will, local infrastructure and available resources. These aspects are important not just for delivering cART and providing health care, but in promoting and monitoring treatment adherence [43]. Required aspects of infrastructure include not only mechanisms to obtain and dispense drugs, but also to teach patients about adverse effects, adherence and lifestyle modifications to improve treatment effectiveness. There is an urgent need for the
development and implementation of simplified, standardized treatment and monitoring algorithms that will facilitate roll-out and scale-up of programs and enable counseling and follow-up of patients.

3. LEVELS AND DETERMINANTS OF ANTIRETROVIRAL THERAPY ADHERENCE IN DEVELOPED COMPARED WITH DEVELOPING COUNTRIES

Historically, there has been an expectation of poor antiretroviral therapy adherence in poverty-affected regions of the world as expressed by selected high-level international agency decision-making bodies. These opinions arguably contributed to the delay in cART roll-out in resource-limited settings [44-46]. Furthermore, until Mills and colleagues conducted a meta-analysis to assess adherence in Africa, comprehensive assessments of levels of cART adherence were limited or based on anecdotes and personal observation. In this meta-analysis, reported levels of adherence were measured in a variety of ways, including pill-counts, pharmacy refill data, Medication Event Monitoring System (MEMS), and self-report [47]. On average, 77% of African patients (95% Confidence Interval [CI]: 68-85%) met the standard definition of good adherence (≥80%) compared to 55% (95% CI: 49-62%) of North American patients. These findings have encouraged international assistance regarding improved access to cART and were referred to by former U.S. President Bill Clinton at the 2006 IAS Conference as the “nail in the coffin” on discrimination regarding drug access [48].

Given the individual and public health benefits associated with adherence to cART, there is a need for a greater understanding of actual adherence rates within specific populations. Moreover, it is vital to examine reasons for poor adherence and possible motivators to improve adherence so as to inform the design of adherence-improving interventions. A review of the literature shows that prevalent factors associated with poor treatment adherence in resource-rich and limited settings include untreated depression, active substance abuse, poor insight into disease and treatment, being an adolescent or young adult, higher pill burden and more frequent dosing, and forgetfulness [49]. In addition, the following risk factors for non-adherence were more prevalent in sub-Saharan Africa: cost or structural barriers such as pharmacy stock-outs or lack of transportation means to the health facility for cART refills [50-51]; food insecurity [52]; non-disclosure to a loved one or fear of being stigmatized [53]. Studies report that the majority of patients accessing cART have disclosed their HIV status to family or friends and that those who have not disclosed appear to have worse outcomes [53]. Patients who do not disclose their infection to their intimate partner or household may have frequent treatment interruptions due to the fact that tablets must be hidden and not taken in the presence of others. Encouraging voluntary HIV status disclosure in a community with access to ART may result in improved uptake of voluntary counseling and testing (VCT) and may help decrease stigma and improve adherence. Of note, very few interventions have been designed that have successfully demonstrated improved adherence, and most have been limited to North American settings [54]. Development of effective, culturally-sensitive cART adherence interventions in developed and developing world settings is an important area of ongoing and future research [54-55].
4. RELATIONSHIP BETWEEN ANTIRETROVIRAL THERAPY ADHERENCE, DRUG CLASS AND DRUG RESISTANCE

The phenomenon of HIV drug resistance continues to receive major clinical and public health attention because resistant HIV not only threatens the patient in which it develops but can be transmitted to others [56]. Widespread resistance has the potential to undermine our ability to fight the HIV/AIDS pandemic by rendering first-line treatments ineffective. This is especially important in the developing world where second-line and salvage regimens are either extremely expensive, unavailable, or both [57].

HIV drug resistance (HIVDR) can be classified as acquired (secondary) or transmitted (primary). Acquired HIVDR occurs when mutations develop to drugs in individuals who have received ARV, often because of poor adherence, treatment interruptions, inadequate drug concentrations, or use of sub-optimal drug combinations leading to treatment failure. Transmitted HIVDR occurs in the context of HIV-infected individuals who have never received ART, and occurs when individuals are newly infected with a drug-resistant virus. If virus replication is not suppressed by medication, millions of viruses harboring different mutations arise each day owing to the high error rate of the reverse transcription process and the lack of genetic proofreading. Although many of these mutations have a detrimental effect on viral survival, occasionally, a mutation results in an altered viral protein which renders viral replication less susceptible to inhibition by a particular antiretroviral drug. In the presence of drug, cART inhibits replication of the wild-type strain, but mutant viral strains with reduced susceptibility continue to replicate and become the predominant circulating viral populations in the individual Fig. (2).

It is grossly apparent that non-adherence to medication invariably breeds drug resistance. However, the relationship between adherence and resistance is much more complex and follow an inverted “U-shaped” curve. At the highest levels of adherence, the threat of resistance is lowest because mutations cannot occur without replication. However, at lower levels of adherence the complex interplay between potency, viral fitness after mutation, the genetic barrier to resistance of cART components, and the other regimen components determine whether or not resistant virus will be circulating Fig. (3). Even relatively small degrees of non-adherence are thought to substantially increase resistance.

The complexity of this relationship is in part determined by the relative fitness of resistant compared with wild type virus. Most mutant strains are less fit than the wild-type strains, which means a certain level of selection pressure is required before the mutant strains are able to out-compete the wild-type strains in order to predominate. As a result, low levels of adherence do not impose the necessary selection pressure on the viral population to favor the resistant less fit strains than the wild-type fitter strains and thus emergence of resistance is less likely. Of course low adherence is not advisable since it allows wild-type virus to replicate unchecked, leading to disease progression. This inverted ‘U-shaped’ relationship leaves moderately adherent patients at the greatest risk for the development of resistance [58].
Work by Bangsberg and others [59-63] has found that the relationship between adherence and drug resistance differs depending on the antiretroviral drug class Fig. (4). Indeed, they have shown that NNRTI-based drug regimens are more likely to produce resistance than PI-based because of several factors. The high potency and long half-life of NNRTIs may lead to better virologic suppression at moderate adherence levels, but paradoxically lead to the development of antiretroviral drug resistance during a treatment interruption of triple therapy containing NRTIs and NNRTI lasting more than 48 hours [64]. During a treatment interruption, the comparatively short half-lives of the NRTIs in the regimen lead to prolonged NNRTI monotherapy. The low genetic barrier for resistance of NNRTIs allows resistant virus to accumulate rapidly. Also, NNRTIs inhibit RT allosterically, by binding to an area outside the active (substrate binding) site, thus NNRTI resistance mutations have little effect on RT’s overall function and hence little impact on viral fitness.

A study in Kampala, Uganda [20], of patients purchasing generic fixed-dose NNRTI-based cART found that 65% had a treatment interruption of greater than 48 hours as evaluated by electronic adherence monitoring, and these treatment interruptions accounted for 90% of missed doses. Eight of the 62 (13%) participants who had treatment interruptions experienced treatment failure due to selection of drug resistant virus, compared to none of the 33 participants without treatment interruptions greater than 48 hours. Importantly, there was also a significant decrease in virologic suppression rates, from 80% to 50%, for patients with ≥95% adherence versus <95% adherence, respectively. As a consequence, the threat of resistance to first-generation NNRTIs is highest at low levels of adherence, rather than at moderate adherence, because even the lowest concentrations of these NNRTIs create enough selection pressure to affect HIV. Protease inhibitors (PIs) and most nucleoside reverse transcriptase inhibitors (NRTIs) require multiple mutations, each of which alter enzyme function and could make the virus less fit [65]. These drugs also have more rapid clearance. It is therefore not surprising that NNRTI resistance is seen more often than PI or NRTI resistance. Reported mutations to NNRTIs, NRTIs, PIs, Entry and Integrase Strand Transfer Inhibitors are updated regularly by the International AIDS Society (IAS)-USA Drug Resistance Group [66] and can be accessed at IAS-USA’s website [67].

5. NON-ADHERENCE TO ANTIRETROVIRAL THERAPY AND ITS IMPACT ON HEALTH CARE COSTS

Nachega et al. [68] found that greater adherence to cART was associated with lower monthly health costs in a private managed care program in South Africa, mainly due to reduced hospital admissions. In contrast, in a U.S. study by Gardner et al. [69], better adherence to cART was associated with higher direct medical costs despite lower rates of hospitalization in more adherent individuals. The differences in the relative contribution of cART costs to overall costs probably accounts for the apparent discrepancy among the studies conducted in South-Africa (where the cART cost component accounted only for 9% of total costs) and in the U.S. (where ART costs represent 60% of total costs). This hypothesis is supported by the fact that overall health care utilization was lower in both the South African and U.S. populations in the setting of better adherence. Other possible explanations include different study methodology, variations in the epidemiology of HIV infection, variations in CD4 T-
cell count at initiation of antiretroviral therapy, structural dissimilarities between health care systems, and differences in health resources consumption. A retrospective cohort analysis within the Adherence sub-study of the Italian Cohort Naïve Antiretroviral (AdICoNA) found that mean annual hospital expenses were significantly higher for non-adherent compared to adherent patients (417 1250 Euro vs. 192 670 Euro; p<0.01). Hence, in this cohort, mostly at early stages of HIV infection and followed-up in Europe, savings in cART costs were associated with non-adherence and offset by the increased risk of hospitalization and the rise in inpatient costs [70].

Antiretroviral therapy is cost-effective in resource-limited and resource-rich settings [71-73]. The data discussed above showed that in resource-limited settings, where cART comprises a smaller proportion of overall health care costs, excellent adherence to antiretroviral therapy is cost saving [68]. In resource-rich settings, better adherence decreases health care utilization, but is not cost saving [69]. However, it is important to note that no formal cost-effectiveness analyses of adherence to antiretroviral therapy have been completed to date. When cost-utility and cost savings that are unmeasurable in system-level studies are taken into account, it is very likely that adherence to antiretroviral therapy will be cost-effective in all settings. Indeed, in United States, the cost-effectiveness of a weekly home visit nursing intervention on antiretroviral adherence (for as much as $1,000 per person) using data from a randomized controlled clinical trial as input to a computer-based state transition model of HIV disease, showed that the incremental cost-effectiveness ratio was $14,100 per quality-adjusted life year gained compared with standard care. Therefore, adherence interventions with modest effectiveness are likely to provide long-term survival benefit to patients and to be cost-effective compared with other uses of HIV care funds [74].

6. MEASURING ANTIRETROVIRAHL THERAPY ADHERENCE

Although adherence is of critical clinical importance, few studies have empirically studied adherence measurement tools [75-78]. Common methods of adherence measurement include pill counts, pharmacy record reviews, self-report measures, electronic monitoring and therapeutic drug monitoring (TDM) [79-80]. To date, there is not a universally accepted tool to measure cART adherence, since each method has distinct advantages and disadvantages including cost, complexity, accuracy, intrusiveness and bias (Table 1). Oyugi et al. [81] evaluated different adherence measurement tools including patient self-report, pill count and MEMS caps, which is an electronic monitoring system. In this pilot study they found excellent agreement between the three measurement tools in a Ugandan HIV cohort with documented high levels of cART adherence. In contrast, Gill et al. [82] found large discrepancies among estimated adherence for different methods when reviewing several cohorts in resource-limited settings. They constructed a relative hierarchy of adherence measurement methods, and reported that physician assessment and self-report were the least accurate, pill counts were intermediate, and electronic monitoring provided the most accurate surrogate of cART adherence. This is similar to the conclusions from a U.S. study which determined that MEMS underestimated adherence while pill counts and patient self-report overestimated adherence [79].
As there is currently no gold standard objective measure of adherence in a real-life setting, studies of adherence typically rely on limited assessment of criterion-related forms of validity such as predictive or concurrent validity. That is, in most cases, validation of an adherence measure is based on how strongly the measure is associated with virologic or other laboratory and clinical outcomes or how well a particular measure compares to other adherence measures [80]. While the ability of measures to predict virologic outcomes is important, it is problematic when the measure is not in fact assessing behavior. For example, if an individual fails therapy due to acquisition of resistant virus, interventions to improve adherence behavior will not be relevant. In addition, some have argued that virologic failure is an inadequate indicator of non-adherence, as several other factors (e.g., viral load level at initiation of cART, potency of the therapy prescribed, individual differences in absorption, and drug interactions) also influence virologic outcomes.

Self-report or pharmacy refills are the most commonly used cART adherence measurement tools in resource-limited settings. These tools can be useful over and above their utility in alerting providers to the need for adherence intervention. Indeed, Bisson et al. [83] reported that pharmacy refill-based adherence levels outperformed CD4 T-cell count changes as a predictor of virologic failure in the first year following cART initiation for patients in Cape Town, South Africa, enrolled in the private sector Aid for AIDS disease management program. In light of this success, there is a need for of the practical implementation of novel, feasible, and cost-effective adherence monitoring tools capable of capturing real-time adherence behavior, which are useful in both resource-limited and resource-rich settings and useful for routine application in clinical care and research studies [77]. Further development of these tools for real-world real-time adherence assessment, linked with interventions to improve adherence when necessary, require further study and will be critically important to the long-term successful utilization of currently available antiretroviral medications.

7. SUMMARY

Adherence to antiretroviral treatment plays a crucial role in the success or failure of therapy for HIV infection. Many barriers to adherence exist and many are shared by developed and developing world settings. No single method for measurement or estimation of adherence has been widely accepted. Further, the relation between adherence and treatment outcomes is complex and likely varies by drug and maybe even by individual. Identifying a simple and affordable method for accurately measuring adherence will facilitate the development of effective, pre-emptive adherence interventions. If applied widely, these interventions will likely prove to be cost-effective in reducing morbidity and mortality when treating large populations in both resource-rich and resource-limited settings.

ACKNOWLEDGEMENT

Funding Sources: The United States National Institutes for Allergy and Infectious Disease (NIAID-NIH), Division of AIDS (DAIDS): K23 AI 068582-01(JBN); and The European Developing Countries Clinical Trial Partnership (EDCTP) Senior Fellowship Award: TA-08-40200-021 (JBN); the National Institute for Allergy and Infectious Disease; T32 AI007438-16 and L30 AI080268-02 (SYH); the NIAID-NIH K01-AI067063 (EMG); the NIMH-NIH R24 MH083592-01A1 (EJM); P30 AH5008 and Agency for Health Research and Quality (AHRQ) U18 HS016946 (RG).
REFERENCES


[50]. Crane JT, Kawuma A, Oyugi JH, Byakika JT, Moss A, Bourgeois P, Bangsberg DR. The price of adherance: qualitative findings from HIV positive individuals purchasing fixed-dose combination


[77]. Bangsberg DR. Monitoring adherence to HIV antiretroviral therapy in routine clinical practice: The past, the present, and the future. AIDS. Behav. 2006; 10:249–251. [PubMed: 16783537]


Fig. (1).
Determinants of HIV Treatment Success and Outcomes.
Fig. (2).
Emergence of Resistant Viral Population due To Selective Drug Pressure.
Fig. (3).
Fig. (4).
Probability of Resistance by Adherence Level and Class of Antiretroviral Therapy Regimen (adapted from reference 60, with permission from Oxford University Press, June 30, 2010).
## Table 1

Antiretroviral Therapy Adherence Monitoring Tools: Accuracy, Advantages and Disadvantages

<table>
<thead>
<tr>
<th>ART Adherence Monitoring Tool</th>
<th>Validity/Reliability</th>
<th>Detection of Adherence Patterns</th>
<th>Real-Time Monitoring</th>
<th>Setting of Use</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-Report</td>
<td>Specific, Very Insensitive, Poor Reliability</td>
<td>Yes</td>
<td>No</td>
<td>Clinical Practice &amp; Research</td>
<td>Low</td>
</tr>
<tr>
<td>Pharmacy Refill or Claim</td>
<td>Specific, Fairly Sensitive &amp; Reliable</td>
<td>No</td>
<td>Could be</td>
<td>Clinical Practice &amp; Research</td>
<td>Low</td>
</tr>
<tr>
<td>Announced or Unannounced Pill Count</td>
<td>Fairly Specific, Fairly Sensitive, Fair Reliability</td>
<td>No</td>
<td>No</td>
<td>Clinical Practice &amp; Research</td>
<td>Low</td>
</tr>
<tr>
<td>Electronic Pill-Container Caps (MEMS caps)</td>
<td>Specific, Too Sensitive &amp; High Reliability</td>
<td>Yes</td>
<td>No</td>
<td>Research</td>
<td>High</td>
</tr>
<tr>
<td>Electronic Web-Enabled Pill Box (Med-eMonitor; Wise Pill; etc.)</td>
<td>Specific, Too Sensitive</td>
<td>Yes</td>
<td>Yes</td>
<td>Research</td>
<td>High</td>
</tr>
<tr>
<td>Directly Observed or Administered Therapy (DOT/DAART)</td>
<td>Specific, Sensitive and Reliable</td>
<td>N/A</td>
<td>Yes</td>
<td>Vulnerable Populations &amp; Research</td>
<td>Labor-Intensive</td>
</tr>
<tr>
<td>Monitoring of Antiretroviral Drug Concentration (Blood, Urine, Hair, etc.)</td>
<td>Specific, Sensitive, Reliable</td>
<td>Yes</td>
<td>Yes</td>
<td>Research</td>
<td>High</td>
</tr>
</tbody>
</table>